Karolina Hurdalkova
YOU?
Author Swipe
View article: 297 LIBUSE trial – algorithm for cervical cancer screening with usage of HPV DNA testing with HPV 16/18 genotyping and p16/Ki-67 dual-stained cytology
297 LIBUSE trial – algorithm for cervical cancer screening with usage of HPV DNA testing with HPV 16/18 genotyping and p16/Ki-67 dual-stained cytology Open
Introduction/Background* The incidence and mortality of cervical cancer in the Czech Republic remains stable over more than 30 years irrespective of existing national screening based on annual collecting of Pap smears. The aim of our prosp…
View article: Real-life Effectiveness of Afatinib <i>Versus</i> Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study
Real-life Effectiveness of Afatinib <i>Versus</i> Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study Open
Afatinib led to longer PFS for patients with common EGFR mutations but not for those with rare mutations.
View article: Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy
Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy Open
In our retrospective study, we point out the possibility of using CYFRA as a prognostic marker in patients with NSCLC treated with chemotherapy plus bevacizumab.
View article: Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy
Laboratory Parameters are Possible Prognostic Markers in Patients with Advanced-stage NSCLC Treated with Bevacizumab plus Chemotherapy Open
Purpose: To investigate potential associations between selected laboratory markers (CRP, LDH, albumin, sodium, hemoglobin, neutrophils, and neutrophils/lymphocytes ratio [NLR]) and outcomes in patients with non-small cell lung cancer (NSCL…
View article: Real‐life effectiveness of first‐line anticancer treatments in stage <scp>IIIB</scp>/<scp>IV NSCLC</scp> patients: Data from the <scp>C</scp>zech <scp>TULUNG R</scp>egistry
Real‐life effectiveness of first‐line anticancer treatments in stage <span>IIIB</span>/<span>IV NSCLC</span> patients: Data from the <span>C</span>zech <span>TULUNG R</span>egistry Open
Background Data regarding real‐life effectiveness of any treatment may improve clinical decision‐making. The aim of this study was to evaluate real‐life effectiveness of tyrosin‐kinase inhibitors, bevacizumab and pemetrexed as first‐line t…
View article: Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non‑small cell lung cancer treated with erlotinib
Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non‑small cell lung cancer treated with erlotinib Open
While erlotinib is primarily administered to patients with non-small cell lung cancer with sensitizing epidermal growth factor receptor (EGFR) mutations, it is also prescribed to patients with wild type (wt) EGFR in higher lines of treatme…
View article: Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer
Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer Open
The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The pres…